Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 14/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.41 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443942 | 0.82 | LTB4R2 (0.62) | LTB4R2AGTR1 | |
| SCHEMBL5091109 | 0.82 | LTB4R2 (0.44) | LTB4R2AGTR2AGTR1ABCC3ABCC4 | |
| SCHEMBL5099365 | 0.80 | LTB4R2 (0.58) | LTB4R2AGTR1 | |
| SCHEMBL27641555 | 0.80 | LTB4R2 (0.58) | LTB4R2AGTR1 | |
| SCHEMBL446695 | 0.80 | LTB4R2 (0.58) | LTB4R2AGTR1 | |
| SCHEMBL5089016 | 0.80 | LTB4R2 (0.46) | LTB4R2AGTR2AGTR1 | |
| SCHEMBL18425480 | 0.79 | LTB4R2 (0.69) | LTB4R2AGTR1 | |
| SCHEMBL9589124 | 0.78 | AGTR1 (0.45) | LTB4R2AGTR2AGTR1 | |
| SCHEMBL443392 | 0.78 | LTB4R2 (0.55) | LTB4R2PTGDR2AGTR1 | |
| SCHEMBL443650 | 0.75 | LTB4R2 (0.65) | LTB4R2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | LTB4R2 1259/4885PTGDR2 780/4885CYP2C8 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.